Biomarkers in Drug formulation

Drug formulation also covers the surrogate end points in the use of biomarkers and patient selection or companion diagnostics and provides insights into clinical biomarker discovery and biomarker development or validation with regulatory implications. Biomarker use can improve pharmaceutical development efficiency by helping to select patients most appropriate for treatment using a given mechanism, optimize dose selection, and provide earlier confidence in accelerating or discontinuing compounds in clinical development.

Biomarker in Drug discovery

 

Biomarker in Drug Design

 

Dose selection in Biomarker

 

Biomarkers of Toxicity & Pharmacology

 

Biomarkers in dose selection

 

Evaluation of dose respons

 

    Related Conference of Biomarkers in Drug formulation

    April 24-25, 2024

    35th European Heart and Heart Failure Congress

    Paris, France
    June 21-22, 2024

    52nd Global Nursing & Healthcare Conference

    Rome, Italy
    August 08-09, 2024

    20th World Congress on Healthcare & Technologies

    London, UK
    September 09-10, 2024

    3rd Global Summit on Physiology and Metabolism of Thyroid

    Paris, France
    September 18-19, 2024

    29th International Conference on Skincare and Cosmetology

    Amsterdam, Netherlands
    September 19-20, 2024

    20th Global Biomarkers and Clinical Research Summit

    Paris, France
    September 24-25, 2024

    5th Global Summit on Public Health

    Paris, France
    November 11-12, 2024

    9th Global Summit on Midwifery and Womens Health

    Dubai, UAE
    November 25-26, 2024

    10th World Holistic Nursing Conference

    Bali, Indonesia
    November 25-26, 2024

    4th International conference on Healthcare Summit

    Bali, Indonesia
    November 28-29, 2024

    World Vaccine Meet 2024

    Bali, Indonesia

    Biomarkers in Drug formulation Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in